1-3 lenf nodu pozitif opere meme kanserinde adjuvan 4 kür siklofosfamid/adriamisin'e 2 kür cisplatin/etoposid eklenmesi ile alınan sonuçların değerlendirilmesi
No Thumbnail Available
Files
Date
2001
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Sağlık Bilimleri Enstitüsü
Abstract
ADJUVANT 2 CYCLES OF CİSPLATİN-ETOPOSİDE FOOLLOWING 4 CYCLES ADRİAMYCİNE-CYCLOPHOSPHAMİDE İN PATIENT OF RESECTABLE BREAST CANCER WITH ONE TO THREE POSITIVE AXILLARY NODES: EVALUATION OF RESULT. Background: Four cycles of adriamycine-cyclophosphamide has been accepted one of the standart adjuvant treatment in breast cancer. In this study we aimed to asses the efficacy of adjuvant cisplatin-etoposid& combination following 4 cycles of standart adjuvant treatment in patient with operabl breast cancer and one to three positive axillary lymph node metastasis. Patient and methods Fifty four patient with one to three axillary positive lymph nodes and who were given two cycles adjuvant cisplatin (70 mg/m2 l.th day i.v)-etoposide (100 mg/m2, 1-7 day, po) combination following four cycles of adriamycine (60 mg/m2 l.th day)-cyclophosphamide (600 mg/m2, l.th day) following radical mastectomy from november 1997 to december 2000 were evaluated retrospectively. Two year disease-free survival (DFS) and overall survival (OS) were assessed with regard to patients characacteristics including age, number of lymph nodes, hormon receptor status* c-erbR2 status, tumor size and grade, vascular and lymphatic invasion, and the time between mastectomy and adjuvant treatment. Results Fifty four patients were included in the study, one of them had undergone bilateral mastectomy because of bilateral breast cancer. Median age was 46 (30-69), and median follow-up was 24.5 (6-44) months. Relapse, and mortality observed in six (11%) and three (5.5%) patients respectively. 29Within a median follow-up period of 24.5 months hasn't been reached at median survival. The end of two year's median follow-up DFS's were 89%, and OS's were 94.5%. Correlation between the DFS, OS and patients characacteristics including age, number of lymph nodes, hormon receptor status, c-erbB2 status, tumors size, tumors grade, vascular and lymphatic invasion were evaluated. No statistical correlation between this parameters and timing of adjuvant chemotherapy on survival. (p> 0.05). Conclusion: Two cycles of adjuvant cisplatin-etoposide combination following four cycles of standart adjuvant treatment in patient with operabl breast cancer and one to three positive axillary lymph node metastasis seems to decrease the relapse rate compared with historic groubs. Long term follow-up is needed. Keywords: Breast cancer, adjuvant chemotherapy, cyclophosphamide-adriamycine cisplatin, etoposide. 30
Description
Keywords
İç Hastalıkları